News | June 17, 2014

Lymphoseek Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes

Ability of receptor-targeted Lymphoseek to accurately target appropriate lymph nodes may lessen patient morbidity from extensive oral cavity surgery

June 17, 2014 — Navidea Biopharmaceuticals Inc. announced results from a post-hoc analysis of patient data from the company’s phase III clinical trial (NEO3-06) of Lymphoseek in head and neck cancer.

The ability of Lymphoseek to localize in sentinel lymph nodes is based on its ability to target specific CD206 mannose receptor sites in macrophages, a type of immune cell that resides in high concentration in lymph nodes. In the NEO3-06 phase III study, Lymphoseek localization to lymph nodes showed a strong correlation with a full regional lymph node dissection and pathology analysis with a low false negative rate, a priority in identifying sentinel nodes. Lymphoseek was also observed to hone preferentially to pathology-positive nodes at a higher rate than pathology-negative nodes. These results suggest that Lymphoseek not only effectively targets sentinel lymph nodes but its ability to highlight tumor-positive lymph nodes may be augmented mechanistically by the recruitment of macrophages to cancer-harboring lymph nodes.

"The accurate detection of tumor-draining lymph nodes is fundamental for effective lymphatic mapping, to minimize lymph tissue removal, and to provide clinically useful information regarding potential cancer metastasis," said Francisco J. Civantos, M.D., FCS, University of Miami School of Medicine. "Approximately 75 percent of patients with stage 1 and 2 oral cavity head and neck cancer may be substantially over-treated if they are subjected to elective neck dissection, which involves surgical removal of a regional lymph node chain involving 30 to 45 lymph nodes. Receptor-targeted radiopharmaceuticals such as Lymphoseek that are designed to facilitate accurate and reliable diagnostic evaluation of specific sentinel lymph nodes can help spare patients morbidity that may result from elective neck dissection procedures."

“As a purpose-built, receptor-targeted radiopharmaceutical, Lymphoseek is designed to target and accumulate in macrophages present in tumor-draining lymphatic tissue,” said Frederick Cope, Ph.D., senior vice president and chief scientific officer of Navidea. “Tumor-positive lymph nodes recruit cells called tumor-associated macrophages, or TAMs, which are rich in CD206 receptors. The ability of Lymphoseek to specifically target and accumulate in macrophages demonstrated in this study led to localization of the product in tumor-draining pathology-positive lymph nodes that was 18 times higher than in all disease-negative lymph nodes. In the clinic, this reliable uptake of Lymphoseek into appropriate tissue allows for accurate removal and assessment of lymph nodes at highest risk of harboring occult metastases.”

The analysis, based on data from the clinical trial, evaluated 83 patients to determine whether Lymphoseek localization in pathology-positive lymph nodes was higher than its localization in pathology-negative nodes, and if those results were consistent with the overall sentinel lymph node population. Sentinel lymph nodes and/or non-sentinel lymph nodes (nodes removed in elective neck dissection, or END) were removed from patients undergoing sentinel lymph node biopsy for head and neck squamous cell carcinoma, and all lymph nodes were assessed for the presence of tumor. Intraoperative counts were obtained for all lymph nodes removed including END nodes. Average in vivo gamma counts for all lymph nodes removed indicated that the count ratio of pathology-positive nodes to pathology negative nodes was approximately 18:1 (p<0.0001). For sentinel lymph nodes only, the ratio was >2.5:1 (p<0.016). The results were presented in an oral session by Frederick Cope of Navidea Biopharmaceuticals at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in St. Louis.

For more information: www.lymphoseek.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init